These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36045284)

  • 21. Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties. Preclinical and early clinical trials in schizophrenia.
    J Clin Psychiatry; 1995 Sep; 56(9):438-45. PubMed ID: 7665549
    [No Abstract]   [Full Text] [Related]  

  • 22. Revisiting the CATIE schizophrenia study. Although questions remain, some clinical guidance has emerged.
    Harv Ment Health Lett; 2008 Jul; 25(1):1-3. PubMed ID: 18777649
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing pharmacotherapy to maximize outcome in schizophrenia.
    Fusion Medical Education LLC
    J Clin Psychiatry; 2005 Jan; 66(1):122-33. PubMed ID: 15669898
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trials for negative symptoms--emerging directions and unresolved issues.
    Marder SR; Rabinowitz J; Kapur S
    Schizophr Res; 2013 Nov; 150(2-3):327. PubMed ID: 24209763
    [No Abstract]   [Full Text] [Related]  

  • 25. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical applications of recent antipsychotic effectiveness data.
    J Clin Psychiatry; 2007 Jan; 68(1):151-62. PubMed ID: 17284143
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence-based pharmacotherapy of schizophrenia.
    Emsley R; Oosthuizen P
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):219-38. PubMed ID: 15043765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [FDA phase II and phase III drug evaluation of antipsychotic agents].
    Yagi K
    Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pipothiazine (piportil) in the treatment of various forms of schizophrenia].
    Matkowski K; Sep-Kowalikowa B
    Psychiatr Pol; 1979; 13(4):421-3. PubMed ID: 42095
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecule of the month. Bifeprunox mesilate.
    Drug News Perspect; 2005 Oct; 18(8):523. PubMed ID: 16391722
    [No Abstract]   [Full Text] [Related]  

  • 31. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 32. Risperidone: a review of efficacy studies in adolescents with schizophrenia.
    Madaan V
    Drugs Today (Barc); 2009 Jan; 45(1):55-62. PubMed ID: 19271032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic effects of AL 1965.
    Sathananthan G; Mir P; Gershon S
    Curr Ther Res Clin Exp; 1976 May; 19(5):516-9. PubMed ID: 7435
    [No Abstract]   [Full Text] [Related]  

  • 34. Myth and reality of pragmatic trials.
    Mohr P; Bitter I; Constant E; Jakovljević M; Jarema M; Pecenak J; Seifritz E; Svestka J; Sartorius N
    Psychiatr Danub; 2010 Mar; 22(1):2-3. PubMed ID: 20305584
    [No Abstract]   [Full Text] [Related]  

  • 35. New developments in the treatment of schizophrenia.
    CME Institute of Physicians Postgraduate Press, Inc
    J Clin Psychiatry; 2007 Mar; 68(3):463-78. PubMed ID: 17388719
    [No Abstract]   [Full Text] [Related]  

  • 36. The CATIE schizophrenia effectiveness trial.
    Delisi LE; Nasrallah HA
    Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
    [No Abstract]   [Full Text] [Related]  

  • 37. Policy toward second-generation antipsychotic drugs: a cautionary note.
    Frank RG
    Psychiatr Serv; 2008 May; 59(5):521-2. PubMed ID: 18451008
    [No Abstract]   [Full Text] [Related]  

  • 38. Risperidone for chronic schizophrenia.
    Med Lett Drugs Ther; 1994 Apr; 36(920):33-4. PubMed ID: 7511777
    [No Abstract]   [Full Text] [Related]  

  • 39. Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders. Part I: Unique patient populations.
    J Clin Psychiatry; 1998 May; 59(5):259-65. PubMed ID: 9632042
    [No Abstract]   [Full Text] [Related]  

  • 40. Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series.
    Gama CS; Lucena DD; Cruz C; Lobato MI; Belmonte-de-Abreu PS
    Braz J Psychiatry; 2010 Jun; 32(2):193-4. PubMed ID: 20658059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.